Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $140.5 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 157.23% year-over-year to $140.5 million in Q1 2026; TTM through Mar 2026 was $140.5 million, a 157.23% increase from a year earlier, with the FY2025 full-year figure at $157.2 million, up 129.67% from the prior year.
• Total Non-Current Liabilities slipped to $140.5 million in Q1 2026 per VRDN's latest filing, from $157.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $157.2 million in Q4 2025 and bottomed at $15.5 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $47.4 million (2023), against an average of $58.5 million.
• Biggest YoY gain for Total Non-Current Liabilities was 162.8% in 2022; the steepest drop was 7.96% in 2022.
• Year by year, Total Non-Current Liabilities stood at $38.9 million in 2022, then advanced by 22.03% to $47.4 million in 2023, then soared by 44.38% to $68.5 million in 2024, then surged by 129.67% to $157.2 million in 2025, then declined by 10.63% to $140.5 million in 2026.
• Per Business Quant, the three latest VRDN Total Non-Current Liabilities figures stand at $140.5 million (Q1 2026), $157.2 million (Q4 2025), and $71.6 million (Q3 2025).